Clinical Trial Update: Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiotherapy with nivolumab and ipilimumab vs radiotherapy with capecitabine for residual disease in triple-negative breast cancer afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Radiotherapy
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Centre Leon Berard | Conditions: Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Status: UNKNOWN